In the present context, increased FX concentrations possibly promote FVIIa/TF-induced FX activation to FXa, and consequently, the additive or synergistic effect on FVIIa/TF-induced FX activation may contribute to augment hemostatic potential in fitusiran-treated people with hemophilia. This evidence concerns the gene F10 and hemophilia.